X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Jocelyn Ulrich

Jocelyn Ulrich Jocelyn Ulrich, MPH, is Deputy Vice President, Policy and Research, at the Pharmaceutical Research and Manufacturers of America (PhRMA). At PhRMA, she is responsible for developing legislative and policy analysis and research studies on a range of issues impacting innovative biopharmaceutical companies including intellectual property issues, FDA policy issues, the R&D process, the value of innovation, and other issue areas impacting the environment for innovation. In addition to her experience at PhRMA she has over 15 years of experience in the pharmaceutical industry at Pfizer, Human Genome Sciences, and EMD Serono in roles in clinical research management, investigator-initiated and collaborative research, and global policy and corporate affairs. Jocelyn holds an MPH in global health policy and management from New York University.

Recent Posts

Protecting treatment advances for breast cancer

By Jocelyn Ulrich  |    October 31, 2022
Since the 1980s, October has been recognized as National Breast Cancer Awareness Month — an opportunity for us to unite as a community to honor those who have had breast cancer and raise awareness...   Read More

Don’t take anti-innovation, activist funded academics at their word

By Jocelyn Ulrich  |    October 18, 2022
It’s disappointing to see yet more studies published by activist-funded industry critics that fail to recognize the nature of competition in the biopharmaceutical market and use cherry-picked data to...   Read More

Biosimilar uptake is increasing and so are health savings

By Jocelyn Ulrich  |    October 17, 2022
There has been a lot of talk recently about the biosimilars marketplace and what role biosimilars play in reducing health care costs. We’re here to set the record straight about how these medicines...   Read More

Research and development continues long after a medicine is initially approved

By Jocelyn Ulrich  |    February 1, 2022
The government’s flawed price setting plan under the Build Back Better Act will significantly upend the biopharmaceutical research and development (R&D) process, risking important advances in patient...   Read More

ICYMI: New report demonstrates growing global impact of antimicrobial resistance

By Jocelyn Ulrich  |    January 24, 2022
New research published in The Lancet shows for the first time the global impact of antimicrobial resistance (AMR), which poses an increasingly serious threat to human health around the world. The...   Read More

Preventing the next public health emergency: New evidence demonstrates need to address antimicrobial resistance

By Jocelyn Ulrich  |    November 18, 2021
COVID-19 is not the first pandemic caused by a novel strain of a virus affecting the upper respiratory tract. Over the past 100 years, pandemics have been caused by novel forms of influenza and other...   Read More

ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response

By Jocelyn Ulrich  |    February 22, 2021
As America’s biopharmaceutical researchers continue working around the clock to fight COVID-19, leaders in the health care ecosystem have come together to provide recommendations to strengthen...   Read More

The next threat: Combatting antimicrobial resistance

By Jocelyn Ulrich  |    February 8, 2021
Since their discovery, antimicrobial medicines have revolutionized the fight against disease and today represent one of the greatest achievements in public health. But after decades of helping to...   Read More

New Graphic: Public-Private collaboration fuels the U.S. biopharmaceutical ecosystem

By Jocelyn Ulrich  |    September 16, 2020
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent...   Read More

R&D Focus: 5 things to know about the biopharmaceutical research ecosystem

By Jocelyn Ulrich  |    July 13, 2020
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates